Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Perrigo Out-Licenses Preclinical Assets to Imago Pharmaceuticals

By Pharmaceutical Processing | September 29, 2014

Perrigo Company has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development company, Imago Pharmaceuticals. Under the terms of the agreement, Perrigo will receive an upfront payment in addition to multiple development-related milestone payments and royalties on any future sales derived from the portfolio.

Perrigo’s Chairman and CEO, Joseph C. Papa stated, “This transaction demonstrates our commitment to focusing our development efforts to those projects where we can best fulfill our ‘Quality, Affordable Healthcare Products®’ mission. Through this sale, we are putting this promising portfolio in the hands of the Imago team to use their expertise to progress them through the development process and, hopefully, improve the lives of patients in the future.”

“We are pleased to have acquired these preclinical assets from Perrigo. They contribute to our internal drug development program by providing drug candidates directed against stress kinase family members,” said Irene Griswold-Prenner, Ph. D., Co-Founder of Imago Pharmaceuticals. “These preclinical assets will provide additional value through strategic partnering with third-parties on a subset of these assets,” added Karen Chen, Ph. D., Co-Founder of Imago Pharmaceuticals. “Included in this acquisition are intellectual property, drug candidates and a 500,000 compound CNS-focused, diversity-driven small-molecule library.”

JRG Ventures, LLC, a multinational retained business development and corporate growth strategy firm specializing in Life Sciences, Healthcare, Health Technology, and novel disruptive technology environments advised Perrigo on this transaction.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE